Our Story

Norway

Built from Oslo by an international team spanning veterinary and human medicine

Norway

Built from Oslo by an international team spanning veterinary and human medicine

Norway

Built from Oslo by an international team spanning veterinary and human medicine

4

Countries where veterinary clinicians already work with Nebumet: Norway, the Netherlands, Ireland and France.

4

Countries where veterinary clinicians already work with Nebumet: Norway, the Netherlands, Ireland and France.

4

Countries where veterinary clinicians already work with Nebumet: Norway, the Netherlands, Ireland and France.

4

Patent families with first grant in UK

4

Patent families with first grant in UK

4

Patent families with first grant in UK

Cancer is one of the leading causes of death in dogs, and one in four dogs will develop cancer in their lifetime. Yet treatment options remain limited, especially once cancer has spread to the lungs. The same is true in people: lung cancer is the leading cause of cancer death worldwide.

We, Immuvera Therapeutics, are a privately owned Norwegian biotech developing inhaled immunotherapy for cancer in dogs and humans. We combine an immune therapy validated in human medicine with a new route of administration, starting with dogs, where the need is urgent and clinical evidence comes faster, and translating that evidence to human lung cancer. That is our One Health approach.

One Health Through Comparative Oncology

Smiling man wearing glasses and a pink shirt, showing his arm with a bandage after vaccination.

What is it?

Comparative oncology is the study of naturally occurring cancers in animals such as pet dogs, so that new treatments developed for them can also improve cancer treatment in humans, and vice versa.

Dogs develop cancer spontaneously, with intact immune systems, much as humans do. Many canine cancers share key biology with human disease, including bone cancer (osteosarcoma), melanoma, breast cancer and lymphoma, and in both species cancer often spreads to the lungs.

Our Strategy

We start where the need is greatest and the evidence comes fastest: dogs with naturally occurring cancer. Clinical studies in dogs show whether a therapy works against real disease, while giving dogs access to new treatment.

Those results then guide and de-risk our human lung-cancer programme. One platform, two medicines, two value paths.

That is what One Health means to us: better cancer care for our dogs today, and a faster route to better cancer care for people tomorrow.

Meet our team

Meet our team

Meet our team

Leadership

Jørund Sollid

Chief Executive Officer

Jørund holds a Ph.D. in Physiology and brings more than 20 years of experience from the pharmaceutical and biotech industries.

He has held senior national and international roles across corporate strategy, commercial operations, business development, deal-making and strategic partnerships. Jørund combines strategic leadership with operational execution and has a strong track record in advancing life science companies through key development and commercial milestones.

Francesca Gatti

Chief Operating Officer

Francesca is a molecular and cellular biologist with a Ph.D. in Biotechnology.

The last 7 years, Francesca has worked in biotech companies developing molecular diagnostic solutions for infectious diseases and cancer. She brings strong operational and scientific experience from early-stage biotechnology, with expertise spanning immunology, biomaterials, diagnostics and translational development.

Lars Moe

Chief Medical Officer

Lars is a former Professor of Small Animal Internal Medicine with more than 40 years of experience as a veterinarian, researcher, educator and leader in veterinary medicine.

His main research focus has been clinical oncology, including cancer causation, hereditary cancers, epidemiology, diagnostics and therapy. Lars also brings extensive international collaboration experience with veterinary faculties, clinicians and leading experts in veterinary oncology.

Mikael Kerboeuf

Chief Scientific Officer

Mikael holds a Ph.D. in Veterinary Medicine from the Norwegian University of Life Sciences.

His research focuses on cancer metastasis and the use of dogs as translational cancer models for human disease. Mikael’s core expertise lies at the intersection of immunology and metastatic cancer biology, with particular focus on how the immune system influences metastatic progression.

Gry Stensrud

Chief Technical Officer

Gry is a pharmacist with a Ph.D. in Pharmaceutical Technology and more than 25 years of experience from the biotech, pharmaceutical and medtech industries.

She has held senior and management roles at GE Healthcare, Photocure and Lytix Biopharma. Gry brings deep expertise in CMC, pharmaceutical development, medical devices, quality systems, regulatory affairs and commercial manufacturing, spanning preclinical development through commercial supply.

Anja Holm

Head of Regulatory Affairs

Anja is a Doctor of Veterinary Medicine from the Royal Veterinary and Agricultural University.

She has close to 25 years of experience in veterinary regulatory affairs, including senior roles at the Danish Medicines Agency and extensive EU regulatory work related to human and veterinary clinical trials.

Anja also served for 12 years on the Committee for Veterinary Medicinal Products at the European Medicines Agency, including six years as Chair of the CVMP.

Amir Sheikh

Fractional Chief Financial Officer

Amir brings more than 15 years of finance experience across medtech, pharma and life sciences companies. He has supported venture-backed start-ups, scale-ups and regulated businesses across fundraising, financial modelling, forecasting, investor reporting, operational finance and finance function development. At Immuvera, Amir supports capital raise preparation, financial planning, investor materials, due diligence readiness and broader financial strategy.

Marie-Paul Lachaud

Head of Clinical Operations

Marie-Paul is a veterinarian with extensive experience in global clinical development and registration of animal health pharmaceuticals. She has held senior roles across veterinary drug development, clinical study oversight and regulatory strategy, including at ICON Clinical Research and Aratana. She also co-founded PROTOCOLE, described as the first European veterinary consultancy and CRO focused on clinical drug development and regulatory affairs. At Immuvera, Marie-Paul supports clinical operations, study execution and registration-oriented development for Nebumet.

Board of Directors

Marcus Sahlin Pettersen

Chair

Jostein Christian Dalland

Member

Benedicte H. Fossum

Member

Kristin Bjerke

Member

Advisory Board

David Argyle

International Medical Advisory Board

Globally recognised veterinary and comparative oncology leader. David is Vice-Principal and Head of the College of Medicine and Veterinary Medicine at the University of Edinburgh, William Dick Chair of Veterinary Clinical Studies, and an RCVS and European-recognised specialist in veterinary oncology.

Henrik Rönnberg

International Medical Advisory Board

Professor of Veterinary Pharmacology at the Swedish University of Agricultural Sciences and Diplomate in Oncology of the European College of Veterinary Internal Medicine – Companion Animals. Henrik brings deep expertise in clinical oncology, pharmacology and translational cancer research in dogs and cats.

Heather Wilson-Robles

International Medical Advisory Board

Veterinary oncologist and Vice President of Research at Ethos Discovery. Heather brings extensive expertise in translational oncology, canine cancer models, clinical research and comparative oncology, with prior leadership as President of the Veterinary Cancer Society.

Latest News

Latest News

Latest News

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Immuvera Therapeutics create value for our shareholders.

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Immuvera Therapeutics create value for our shareholders.

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Immuvera Therapeutics create value for our shareholders.